FDA OKs generic version of Merck bronchospasm med (NYSE:MRK)

The FDA approves Mumbai-based Cipla Limited’s generic version of Merck’s (MRK +2.6%) Proventil HFA (albuterol sulfate) Metered Dose Inhaler, 90 mcg/Inhalation for the treatment or prevention of bronchospasm in patients at least four years old who have reversible obstructive airway disease and the prevention of exercise-induced bronchospasm.

This is the first generic Proventil HFA approved in the U.S.

Facebook Comments

Leave a Reply

Your email address will not be published. Required fields are marked *